The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD

Figure 2

Scatterplot of the central retinal thickness before and after switching to brolucizumab. The red dots represent eyes with a ≥50 μm increase in retinal thickness at 12 months compared to Base line.